What is the purpose of the REPLACE-1 and REPLACE-2 trials?
The REPLACE-1 and REPLACE-2 trials were randomized trials that compared bivalirudin to heparin during percutaneous coronary intervention (PCI) to assess the efficacy of bivalirudin in reducing clinical events. The REPLACE-1 trial found that bivalirudin was associated with a 24% reduction in major adverse cardiac events compared to heparin. The REPLACE-2 trial found that bivalirudin plus provisional glycoprotein IIb/IIIa blockade was associated with a 25% reduction in major adverse cardiac events compared to heparin plus planned glycoprotein IIb/IIIa blockade. 